GT Biopharma, Inc. (GTBP) earnings date, results and what the price requires
Nasdaq · SEC CIK 0000109657 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | — | $-4.5M | $-0.12 | Filing |
| Mar 31, 2026 | May 15, 2026 | — | $-2.8M | $-0.11 | Filing |
| Dec 31, 2025 | Mar 2, 2026 | — | $-5.7M | $3.53 | Filing |
| Sep 30, 2025 | Nov 14, 2025 | — | $8.3M | $1.04 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | — | $-30.2M | $-10.92 | Filing |
| Mar 31, 2025 | May 15, 2025 | — | $-776,000 | $-0.33 | Filing |
| Dec 31, 2024 | Feb 21, 2025 | — | $-3.8M | $-1.60 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | — | $-3.4M | $-1.53 | Filing |
What would GT Biopharma, Inc. have to report for its valuation to change?
At $7.03, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -32.7% a year, to $0.60. On that path the next quarter needs diluted EPS near $0.70, against $1.04 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -32.7% | -32.7% |
| EPS needed in final year | $0.60 | $0.60 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. GTBP goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.